APVO | tickerfilter.com

Fundamental analysis

38%

Profitability 35%

Dept financing 35%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-9.73%

1 Month

-7.25%

3 Months

377.61%

6 Months

332.43%

1 Year

151.97%

2 Year

-3.03%

Key data

Stock price

$6.40

P/E Ratio

0.00

DAY RANGE

$6.35 - $6.51

EPS

-$37.88

52 WEEK RANGE

$0.24 - $13.11

52 WEEK CHANGE

$148.06

MARKET CAP

4.767 M

YIELD

N/A

SHARES OUTSTANDING

16.850 M

DIVIDEND

$0.00

EX-DIVIDEND DATE

12-04-2024

NEXT EARNINGS DATE

05-07-2025

BETA

2.22

PUBLIC FLOAT

AVERAGE 10 VOLUME

$19,496

AVERAGE 30 VOLUME

$27,871

Company detail

CEO: Marvin L. White
Region: US
Website: aptevotherapeutics.com
Employees: 50
IPO year: 2016

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Aptevo Therapeutics Inc. focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company also has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.

APVO - Aptevo Therapeutics Inc.